University of Notre Dame Du Lac

Klinikum Der Universitat Munchen

Wolff Cellulosics Gmbh Co. Kg

Hsiri Therapeutics, Inc.

Leibniz-institut Für Naturstoff-forschung Und Infektionsbiologie E.v. -hans-knöll-institut- (hki)

Ute Möllmann

Marvin J Miller

Thomas Heinze

Hans-Martin Dahse

Patricia Miller

Michaela Schmidtke

Manuka Ghosh

Yun-Ming Lin

Axel Brakhage

Florian Kloss

Kamil Philip Wojtas

Julia Dreisbach

Sebastian Schieferdecker

Vera Haack

Albert Härtl

Vadim A Makarov

Stewart T Cole

Vadim Makarov

T Cole Stewart

The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. In a preferred embodiment the invention is concerned with compounds of the general formula (I) whereinRrepresents NO,Rrepresents CF,at least one of the substituents Rand Ris OH, SR, NHR, CN, N, a saturated or unsaturated, optionally halogenated, linear or branched aliphatic radical having 1-4 carbon atoms, linear or branched C-Calkoxy, C-Cacyl, and the other of Rand Rmay in addition be hydrogen,Rrepresents a 2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl or a 4-(cyclo-hexylmethyl)piperazin-1-yl group andRand Rindependently of each other are hydrogen or a C-Calkyl group and/or a pharmaceutically acceptable salt thereof.

Antimicrobial compounds, their use for the treatment of mammalian infections and a new metabolic mechanism

A compound, comprising: an Fe(III)-binding and/or Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; and daptomycin covalently bound to the linker, or, if no linker is present, then to the siderophore; or pharmaceutically acceptable salt or solvate thereof.

Antibacterial sideromycins

The present invention relates to a method of treating infectious diseases, that involves: (a) providing an alpha-glycosidically linked starch polysaccharide derivative; and (b) inhibiting the growth of an infectious disease by administering a composition comprising the alpha-glycosidically linked starch polysaccharide derivative. The alpha-glycosidically linked starch polysaccharide derivative represented by the following general formula I, in which: the alpha-glycosidically linked starch polysaccharide derivative has a degree of quaternary ammonium group substitution of from 0.4 to 2.0; n is 2-4; Ris selected from the group consisting of Calkyl, benzyl and benzyl substituted with a member selected from the group consisting of Calkyl, halogen, alcoxy, carbamoyl, alkoxycarbonyl, cyano, dialkylamino and hydrogen; Rand Rare each independently selected from the group consisting of Calkyl, benzyl and benzyl substituted with a member selected from the group consisting of Calkyl, halogen, alcoxy, carbamoyl, alkoxycarbonyl, cyano and dialkylamino; and X is an anion selected from the group consisting of halide, hydroxide, sulfate, hydrogen sulfate and carboxylate.

Method of treating infectious diseases with polysaccharide derivatives

Growing community of inventors

Jena, Germany

Ute Möllmann